About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Asxl1tm1.1Iaai
targeted mutation 1.1, Iannis Aifantis
MGI:5575656
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tg(VAV1-cre)1Graf/0 		involves: 129S/SvEv * C57BL/6 MGI:5575662
cn2
 		Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0 		involves: 129S/SvEv * C57BL/6 MGI:5575663
cn3
 		Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tg(Mx1-cre)1Cgn/0 		involves: 129S/SvEv * C57BL/6 * CBA MGI:5575661
cn4
 		Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/0 		involves: 129S/SvEv * C57BL/6 * CBA MGI:5575664


Genotype
MGI:5575662
cn1
Allelic
Composition		 Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tg(VAV1-cre)1Graf/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Asxl1tm1.1Iaai mutation (1 available); any Asxl1 mutation (116 available)
Tg(VAV1-cre)1Graf mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal definitive hematopoiesis ( J:208092 )
• increase in the absolute number of immunophenotypically defined hematopoietic stem cells at 6 weeks of age, however a decrease in serial plating in vitro is seen, indicating a defect in self-renewal of hematopoietic stem cells
• transplantation experiments show that hematopoietic stem cells show impaired self-renewal
• transplantation of whole bone marrow from mutants into lethally irradiated recipients results in a lethal hematopoietic disorder
abnormal myelopoiesis ( J:208092 )
• 6 month old mice show dysplasia of circulating myeloid cells
• analysis of sorted myeloid progenitor cells from 6 week old mice shows a decrease in colony output of sorted common myeloid progenitors, granulocyte/macrophage progenitors, and megakaryocyte/erythroid progenitors
anemia ( J:208092 )
• develop progressive anemia that is most apparent at 6-12 months of age
decreased bone marrow cell number ( J:208092 )
• mice develop progressive bone marrow hypocellularity beginning at 6 weeks of age that is still seen at 24 weeks of age
increased erythroid progenitor cell number ( J:208092 )
• 1.4- to 2-fold increase in CD71+/Ter119- erythoroid precursor cells in the bone marrow and spleen, indicating impaired erythroid differentiation
decreased hemoglobin content ( J:208092 )
• hemoglobin is reduced at between 6 and 12 months of age, but not in mice younger than 6 months
increased nucleated erythrocyte cell number ( J:208092 )
• 6 month old mice show frequent circulating nucleated red cells
decreased leukocyte cell number ( J:208092 )
• develop progressive leukopenia that is most apparent at 6-12 months of age
• leukopenia is predominately as a result of decreased B220+ mature B cells, CD11b+Gr1+ neutrophils, and CD11b+Gr1- monocytes
decreased neutrophil cell number ( J:208092 )
• decrease in CD11b+Gr1+ neutrophils
decreased mature B cell number ( J:208092 )
• decrease in B220+ mature B cells
decreased monocyte cell number ( J:208092 )
• decrease in CD11b+Gr1- monocytes
abnormal hematopoietic stem cell morphology ( J:208092 )
• mice show increased apoptosis and altered cell cycle distribution (decrease in S-phase) of hematopoietic stem cells
increased hematopoietic stem cell number ( J:208092 )
• mice show an increase in the frequency and total number of hematopoietic stem cells
decreased splenocyte number ( J:208092 )
• mice develop progressive splenic hypocellularity beginning at 6 weeks of age that is still seen at 24 weeks of age

immune system
abnormal myelopoiesis ( J:208092 )
• 6 month old mice show dysplasia of circulating myeloid cells
• analysis of sorted myeloid progenitor cells from 6 week old mice shows a decrease in colony output of sorted common myeloid progenitors, granulocyte/macrophage progenitors, and megakaryocyte/erythroid progenitors
decreased leukocyte cell number ( J:208092 )
• develop progressive leukopenia that is most apparent at 6-12 months of age
• leukopenia is predominately as a result of decreased B220+ mature B cells, CD11b+Gr1+ neutrophils, and CD11b+Gr1- monocytes
decreased neutrophil cell number ( J:208092 )
• decrease in CD11b+Gr1+ neutrophils
decreased mature B cell number ( J:208092 )
• decrease in B220+ mature B cells
decreased monocyte cell number ( J:208092 )
• decrease in CD11b+Gr1- monocytes
decreased splenocyte number ( J:208092 )
• mice develop progressive splenic hypocellularity beginning at 6 weeks of age that is still seen at 24 weeks of age

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
myelodysplastic syndrome DOID:0050908 OMIM:614286
 J:208092




Genotype
MGI:5575663
cn2
Allelic
Composition		 Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(VAV1-cre)1Graf/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Asxl1tm1.1Iaai mutation (1 available); any Asxl1 mutation (116 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (778 available)
Tg(VAV1-cre)1Graf mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
hematopoietic system phenotype ( J:208092 )
N
• colony assays of whole bone marrow cells show restored serial-replating capacity of cells and competitive transplantation experiments show restoration of the self-renewal defect seen in single conditional Asxl1 mutants




Genotype
MGI:5575661
cn3
Allelic
Composition		 Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tg(Mx1-cre)1Cgn/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Asxl1tm1.1Iaai mutation (1 available); any Asxl1 mutation (116 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal myelopoiesis ( J:208092 )
• 6 month old mice show dysplasia of circulating myeloid cells following pI:pC treatment
extramedullary hematopoiesis ( J:208092 )
• mice treated with polyinosinicpolycytidylic acid (pI:pC) show infiltration of liver with hematopoietic cells, indicating extramedullary hematopoiesis
increased erythroid progenitor cell number ( J:208092 )
• 1.4- to 2-fold increase in CD71+/Ter119- erythoroid precursor cells in the bone marrow and spleen following pI:pC treatment, indicating impaired erythroid differentiation
decreased hemoglobin content ( J:208092 )
• hemoglobin is reduced at between 6 and 12 months of age after pI:pC treatment, but not in younger mice
increased nucleated erythrocyte cell number ( J:208092 )
• following pI:pC treatment, mice show frequent circulating nucleated red cells at 6 months of age
decreased leukocyte cell number ( J:208092 )
• following pI:pC treatment, mice develop progressive leukopenia that is most apparent at 6-12 months of age
• leukopenia is predominately as a result of decreased B220+ mature B cells, CD11b+Gr1+ neutrophils, and CD11b+Gr1- monocytes
decreased neutrophil cell number ( J:208092 )
• decrease in CD11b+Gr1+ neutrophils following pI:pC treatment
decreased mature B cell number ( J:208092 )
• mice show a decrease in B220+ mature B cells following pI:pC treatment
decreased monocyte cell number ( J:208092 )
• decrease in CD11b+Gr1- monocytes following pI:pC treatment

immune system
abnormal myelopoiesis ( J:208092 )
• 6 month old mice show dysplasia of circulating myeloid cells following pI:pC treatment
decreased leukocyte cell number ( J:208092 )
• following pI:pC treatment, mice develop progressive leukopenia that is most apparent at 6-12 months of age
• leukopenia is predominately as a result of decreased B220+ mature B cells, CD11b+Gr1+ neutrophils, and CD11b+Gr1- monocytes
decreased neutrophil cell number ( J:208092 )
• decrease in CD11b+Gr1+ neutrophils following pI:pC treatment
decreased mature B cell number ( J:208092 )
• mice show a decrease in B220+ mature B cells following pI:pC treatment
decreased monocyte cell number ( J:208092 )
• decrease in CD11b+Gr1- monocytes following pI:pC treatment

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
myelodysplastic syndrome DOID:0050908 OMIM:614286
 J:208092




Genotype
MGI:5575664
cn4
Allelic
Composition		 Asxl1tm1.1Iaai/Asxl1tm1.1Iaai
Tet2tm1.1Iaai/Tet2tm1.1Iaai
Tg(Mx1-cre)1Cgn/0
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Asxl1tm1.1Iaai mutation (1 available); any Asxl1 mutation (116 available)
Tet2tm1.1Iaai mutation (2 available); any Tet2 mutation (778 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:208092 )
• 40% of mice treated with polyinosinicpolycytidylic acid (pI:pC) at 4 weeks of life die by 50 weeks of age

hematopoietic system
abnormal myelopoiesis ( J:208092 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pI:pC results in a myelodysplastic syndrome and mice exhibit lower white blood cell counts and hematocrit, presence of dysplastic erythroid precursors, dysplastic myloid cells, and increased extramedullary hematopoiesis

immune system
abnormal myelopoiesis ( J:208092 )
• transplantation of bone marrow from mutants into lethally irradiated CD45.1 recipient mice that were treated with pI:pC results in a myelodysplastic syndrome and mice exhibit lower white blood cell counts and hematocrit, presence of dysplastic erythroid precursors, dysplastic myloid cells, and increased extramedullary hematopoiesis




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/23/2024
MGI 6.23 		The Jackson Laboratory